1Candotto V, Lauritano D, Nardone M, Baggi L, Arcuri C, Gatto R, et al. (2017) HPV infection in the oral cavity: epidemiology, clinical manifestations, and relationship with oral cancer. J Oral Implantol 10: 209-220.

2Marur S, Forastiere AA (2016) Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 91: 386-96.

3Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 25: 1627.

4Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. (2017) Human Papillomavirus and Related Diseases in the World. Summary of Report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Center).

5(2017) World Health Organization [Internet]. Human papilloma-virus.

6Husain N, Neyaz A (2017) Human papillomavirus-associated head and neck squamous cell carcinoma: controversies and new concepts. J Oral Biol Crani-ofac Res 7: 198-205.

7Tovar Martín MI, Martínez Carrillo MJ, Guerrero Tejada R (2012) Human papillomavirus detection in head and neck squamous cell carcinomas and it's clinical implications. In: Poblet Martínez E, editor. Histopathology - reviews and recent advances: InTech.

8Azúa Romeo J (2005) The role of p16 modulator in human papillomavirus infection. Rev Clin Esp. 205: 248-251.

9Sanabria Negrín JG (2009) Human Papillomavirus / Human Papillomavirus (HPV). Pinar del Río Journal of Medical Sciences 13: 168-187.

10Giarré M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tommasino M (2001) Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16 ink4a-imposed G1 cell cycle arrest. J Virol 75: 4705-4712.

11Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T (1998) Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 53: 1741-1748.

12Belobrov S, Cornall AM, Young RJ, Koo K, Angel C, Wiesenfeld D, et al. (2018) The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med 47:18-24.

13Lim S, Lee MJ, Cho I, Hong R, Lim SC (2016) Efficacy of p16 and Ki-67 immunostaining in the detection of squamous intraepithelial lesions in a high-risk HPV group. Oncol Lett 11:1447-452.

14Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade B, Sun D, Duensing S, Sheets E, Munger K, Crum C (2001) Ki 67, cyclin E and p16 ink4a are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J SurgPatho 25: 884-891.

15Contreras W, Venegas B (2015) Virus papiloma humano en cáncer oral y orofaríngeo. Revisión de la Literatura. Int J Odontostomat 9: 427-435.

16Abbas T, Dutta A (2009) P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414.

17Taberna M, Mena M, Pavón MA, Alemany L, et al. (2017) Human papillomavirus-related oropharyngeal cancer. Ann Oncol 28: 2386-2398.

18González Díaz M, Motta Vargas LA, Moreno Torres A, Chala Galindo AI, TupazErira HA, García Robayo DA (2014) Human papillomavirus infection affects the prognosis of squamous oropharyngeal cancer. Literature Review. Univ Odontol 33: 55-63.

19D'Souza G, McNeel TS, Fakhry C (2017) Understanding personal risk of oropharyngeal cancer: risk groups for oncogenic oral HPV infection and oropharyngeal cancer. Ann Oncol 28: 3065-3069.